Nebivolol induces a hyperpolarizing effect on smooth muscle cells in the mouse renal artery by activation of beta-2-adrenoceptors

Pharmacology

Volumn 81, Issue 2, 2008, Pages 110-117

  Georgescu, A ^a,b   Pluteanu, F ^a   Flonta, M L ^a   Badila, E ^b   Dorobantu, M ^b   Popov, D ^a  

^a UNIVERSITY OF BUCHAREST   (Romania)

^b INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Hyperpolarization; Nebivolol; Renal artery; Vasodilation

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BUTOXAMINE; CALCIUM ACTIVATED POTASSIUM CHANNEL; IBERIOTOXIN; NEBIVOLOL; NITRIC OXIDE; TETRYLAMMONIUM;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HYPERPOLARIZATION; IN VITRO STUDY; MOUSE; MOUSE STRAIN; MYOGRAPHY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RENAL ARTERY; SMOOTH MUSCLE FIBER; VASODILATATION;

EID: 38749083403     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110011     Document Type: Article

References (31)

1. + channels in genetic and nongenetic hypertension. Circ Res 1996;79:295-301.
2. De Vriese AS, Van de Voorde J, Vanhoutte PM, Verbeke M, Lameire NH: The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia 2000;43:1116-1125.
3. Cosentino F, Bonetti S, Rehori R, Eto M, Werner-Felmayer G, Luscher TF: Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta 1-selective receptor blockade. J Hypertens 2002;20:421-428.
4. Ignarro L, Byrns R, Trinh K, Sisodia M, Buga G: Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 2002;7:75-77.
5. McNeely W, Goa KL: Nebivolol in the management of essential hypertension: a review. Drugs 1999;57:633-651 [published erratum appears in Drugs 1999;57:870].
6. Waeber B: Nebivolol: a beta blocker with vasodilator properties. Schweiz Rundsch Med Prax 2000;89:631-633.
7. Scheen AJ: Pharma-clinics medication of the month. Nebivolol (Nobiten). Rev Med Liege 2001;56:788-791.
8. Broeders MA, Doevendans PA, Bekkers BC, Bronsaer R, Van Gorsel E, Heemskerk JW, Egbrink MG, Van Breda E, Reneman RS, Van Der Zee R: Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta (2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-684.
9. Altwegg LA, D'Uscio LV, Barandier C, Cosentino F, Yang Z, Luscher TF: Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries. J Cardiovasc Pharmacol 2000;36:316-320.
10. Ritter JM: Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 2001;38:13-16.
11. De Groot AA, Mathy, MJ, van Zwieten PA, Peters SL: Involvement of the beta 3 adrenoreceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol 2003;42:232-236.
12. Parenti A, Filippi S, Amerini S, Granger HJ, Fazzini A, Ledda F: Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000;292:698-703.
13. Andre DE, Arnet U, Yang Z, Luscher TF: Nebivolol inhibits human aortic smooth muscle cell growth: effects of cell cycle regulatory proteins. J Cardiovasc Pharmacol 2000;35:845-848.
14. Brehm BR, Bertsch D, von Fallois J, Wolf SC: Beta - blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000;36:5401-5403.
15. Brehm BR, Wolf SC, Bertsch D, Klaussner M, Wesselborg S, Schulze-Osthoff K: Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001;49:430-439.
16. Gosgnach W, Boixel C, Nevo N, Poiraud T, Michel JB: Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway. J Cardiovasc Pharmacol 2001;38:191-199.
17. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frolich JC: Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 2000;50:377-379.
18. Janssen PM, Zeitz O, Rahman A, Hasenfuss G: Protective role of nebivolol in hydroxyl radical induced injury. J Cardiovasc Pharmacol 2001;38:17-23.
19. Georgescu A, Pluteanu F, Flonta M-L, Badila E, Dorobantu M, Popov D: The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 2005;508:159-166.
20. Kristova V, Kriska M, Vojtko R, Kurtansky A: Effect of indomethacin and deendothelisation on vascular responses in the renal artery. Physiol Res 2000;49:129-133.
21. Mulvany MJ, Halpern W: Contractile properties of small arteriolar resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1997;41:19-26.
22. Akata T, Nakashima M, Kodama K, Boyle W, Takahashi S: Effects of volatile anesthetics on acetylcholine-induced relaxation in the rabbit mesenteric resistance artery. Anesthesiology 1995;82:188-204.
23. Chulia T, Gonzales P, Del Rio M, Tejerina T: Comparative study of elgodipine and nisoldipine on the contractile response of various isolated blood vessels. Eur J Pharmacol 1995;285:115-122.
24. Thurston G, Baldwin AL, Wilson LM: Changes in endothelial actin cytoskeleton at leakage sites in the rat mesenteric vasculature. Am J Physiol 1995;266:316-329.
25. + channel openers on relaxations to nitric oxide and endothelium-derived hyperpolarizing factor in rat mesenteric artery. Eur J Pharmacol 1998;357:41-51.
26. Tschudi MR, Mesaros Stefan, Lüscher TF, Malinski T: Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Hypertension 1996;27:32-35.
27. Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM: Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991;17:964-969.
28. Ladage D, Brixius K, Hoyer H, Steingen C, Wesseling A, Malan D, Bloch W, Schwinger R: Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol 2006;33:720-724.
29. 3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004;110:948-954.
30. Forstermann U, Schmidt HHW, Pollock JS, Sheng H, Mitchell JA, Warner TD, Nakane M, Murad F: Isoforms of nitric oxide synthase: characterization and purification from different cell types. Biochem Pharmacol 1991;42:1848-1857.
31. Moncada S, Palmer RMJ, Higgs A: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-142.